AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value

$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

Quarterly Annual

Latest, FY2025

493

Period ended Dec 31, 2025

Change on a year earlier

-0.2%

494 in FY2024

History

5 years

Since FY2021

Sources

Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	493	-0.2%	Form 10-K (filed 2026-02-20) ↗
FY2024	Dec 31, 2024	494	+4.7%	Form 10-K (filed 2026-02-20) ↗
FY2023	Dec 31, 2023	472	+10.3%	Form 10-K (filed 2026-02-20) ↗
FY2022	Dec 31, 2022	428	+2.4%	Form 10-K (filed 2025-02-14) ↗
FY2021	Dec 31, 2021	418	–	Form 10-K (filed 2024-02-20) ↗

Breakdown

What makes up ozurdex (dexamethasone intravitreal implant) — worldwide net revenues ($m)

Cite this data

StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex_ww

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.